Sugi Predict

Sugi Predict / Compounds / SCHEMBL4389183

SCHEMBL4389183

SCHEMBL4389183

COC(=O)/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)CCC1(C)C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.76
▸ ALOX15 P16050 4/20 0.76
▸ ALDH1A1 P00352 9/20 0.54
▸ RXRA P19793 5/20 0.54
▸ CYP3A4 P08684 5/20 0.54
▸ RARA P10276 4/20 0.54
▸ RARB P10826 4/20 0.54
▸ RARG P13631 4/20 0.54
▸ PTGS1 P23219 4/20 0.54
▸ HIF1A Q16665 4/20 0.54
▸ MAPK1 P28482 3/20 0.54
▸ BLM P54132 3/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ LMNA P02545 3/20 0.54
▸ HSD17B10 Q99714 3/20 0.54
▸ RXRB P28702 2/20 0.54
▸ RXRG P48443 2/20 0.54
▸ RORC P51449 2/20 0.54
▸ ADORA3 P0DMS8 2/20 0.54
▸ HTR2B P41595 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17769829 1.00 MAPT (0.76) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL7088911 1.00 MAPT (0.76) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL4389190 1.00 MAPT (0.76) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL5905823 0.90 MAPT (0.74) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL10067470 0.89 MAPT (0.72) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL3389048 0.89 MAPT (0.72) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL1717832 0.88 MAPT (0.71) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL20622733 0.88 MAPT (0.57) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL25378972 0.87 MAPT (0.81) MAPTALOX15ALDH1A1RXRACYP3A4
SCHEMBL161114 0.87 MAPT (0.81) MAPTALOX15ALDH1A1RXRACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021127438-A1 COMPOSITION AND METHOD FOR TREATING DERMATOLOGICAL DISORDERS USING RETINAMIDES UNIVERSITY OF MARYLAND, BALTIMORE (US) 2021-06-24 — — WO disclosed
CN-112142635-A Preparation method of olefine acid impurity 重庆华邦胜凯制药有限公司 2020-12-29 — — CN disclosed
US-9156792-B2 Retinamide and uses thereof UNIVERSITY OF MARYLAND, BALTIMORE (US) 2015-10-13 — — US disclosed
US-9156792-B2 Retinamide and uses thereof UNIVERSITY OF MARYLAND, BALTIMORE (US) 2015-10-13 — — US disclosed
US-8481011-B2 Use of polyunsaturated compounds as whitening agents PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-07-09 — — US disclosed
EP-1734944-B1 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER FOND IRCCS ISTITUTO NAZ DEI TUMORI (IT) 2012-06-13 — — EP disclosed
US-20110059974-A1 NOVEL RETINAMIDE RETINOIC ACID METABOLISM BLOCKING AGENTS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2011-03-10 — — US disclosed
US-20110059974-A1 NOVEL RETINAMIDE RETINOIC ACID METABOLISM BLOCKING AGENTS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2011-03-10 — — US disclosed
US-20090304614-A1 Use of Polyunsaturated Compounds as Whitening Agents PIERRE FABRE DERMO-COSMETIQUE (FR) 2009-12-10 — — US disclosed
US-7169813-B2 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer Fondazione IRCCS “Istituto Nazionale Dei Tumori” (IT) 2007-01-30 — — US disclosed
EP-1734944-A1 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (IT) 2006-12-27 — — EP disclosed
US-20060264514-A1 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" (IT) 2006-11-23 — — US disclosed
WO-2005092314-A1 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEL TUM (IT) 2005-10-06 — — WO disclosed
EP-0498883-A4 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS — 1993-03-10 — — EP disclosed
EP-0498883-A1 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS SOUTHERN RESEARCH INSTITUTE (US) 1992-08-19 — — EP disclosed
US-5124083-A Anticarcinogenic agents SOUTHERN RESEARCH INSTITUTE (US) 1992-06-23 — — US disclosed
WO-1992004432-A1 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS SOUTHERN RESEARCH INSTITUTE (US) 1992-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059974-A1 NOVEL RETINAMIDE RETINOIC ACID METABOLISM BLOCKING AGENTS RARB, RARA, RARG MAPT 2030/4885ALOX15 1264/4885ALDH1A1 94/4885
US-20060264514-A1 4-OXO-FENRETINIDE, ADMINISTERED ALONE AND IN COMBINATION WITH FENRETINIDE, AS PREVENTIVE AND THERAPEUTIC AGENT FOR CANCER NR2E3, NR4A3, NR4A2 MAPT 3897/4885ALOX15 1596/4885ALDH1A1 719/4885
US-20090304614-A1 Use of Polyunsaturated Compounds as Whitening Agents FASN, ALOX5, ALOX15B MAPT 2405/4885ALOX15 5/4885ALDH1A1 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.